As the literature states, a PD-L1 checkpoint is functional in tumor-associated macrophages [89] and is regarded as a major driver in numerous types of cancers, and anti-PD-L1/PD-1 drugs qualify for the therapy of cancer [90]. The gene discussed is CD274; the disease is cancer.